CSL’s High Hopes For Heart Attack Therapy Come Crashing Down

The Australian firm has reported disappointing results from an 18,200-patient trial of its plasma-derived apolipoprotein A-I therapy which did not cut the risk of major adverse cardiovascular events following acute myocardial infarction.